Adamis pharmaceuticals corporation issues nationwide voluntary recall of symjepi® (epinephrine) injection for potential manufacturing defect

San diego, march 21, 2022 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) is voluntarily recalling certain lots of symjepi (epinephrine) injection 0.15 mg (0.15 mg/0.3 ml) and 0.3 mg (0.3 mg/0.3 ml) pre-filled single-dose syringes to the consumer level. the batches in the table below are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. us worldmeds (uswm) exclusively markets and distributes symjepi in the united states, under license from adamis, the nda holder. uswm will handle the entire recall process for adamis, with adamis oversight. symjepi is manufactured and tested for adamis by catalent belgium s.a.
ADMP Ratings Summary
ADMP Quant Ranking